Beta Cell Imaging During and Shortly After the Honeymoon Phase of T1D

NCT03917238 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing a new imaging method to measure beta cell activity in the pancreas of people recently diagnosed with type 1 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 14 people Planned (estimated).

Who can join Ages 16+ · all sexes

Timeline Started 2019-10 · est. completion 2026-12

Where 2 sites · Netherlands

What this study is testing ClinicalTrials.gov NCT03917238 ↗

Description as written by the study sponsor.

The primary goal is to correlate beta cell mass to beta cell function from measurements during and shortly after the honeymoon phase of type 1 diabetes, to improve understanding of the change in metabolic control after the honeymoon phase.

Treatments tested

gallium-68-exendin injection followed by PET/CT scan Radiation

After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended

Main thing measured	Pancreatic uptake of gallium-68-NODAGA-exendin-4
Sponsor	Radboud University Medical Center
Conditions studied	Type 1 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03917238 ↗